-
公开(公告)号:PT95216A
公开(公告)日:1991-05-22
申请号:PT9521690
申请日:1990-09-05
Applicant: ABBOTT LAB
Inventor: ROSENBERG SAUL H , SHAM HING L
IPC: A61K31/195 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4427 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K38/00 , A61P9/00 , A61P9/12 , A61P13/02 , A61P15/00 , A61P17/00 , A61P43/00 , C07C215/10 , C07C215/20 , C07C229/06 , C07C229/36 , C07C233/36 , C07C233/47 , C07C235/08 , C07C259/20 , C07C265/08 , C07C271/16 , C07C271/22 , C07C271/48 , C07C275/24 , C07C309/24 , C07C309/82 , C07C317/28 , C07C317/44 , C07C323/25 , C07C323/41 , C07C323/52 , C07C323/60 , C07C327/22 , C07C327/60 , C07D205/04 , C07D207/12 , C07D213/40 , C07D231/12 , C07D263/20 , C07D263/24 , C07D277/20 , C07D277/30 , C07D277/42 , C07D277/46 , C07D295/145 , C07D295/18 , C07D295/185 , C07D295/205 , C07D295/215 , C07D401/12 , C07D403/12 , C07D417/12 , C07D513/04 , C07D521/00 , C07K1/113 , C07K5/06 , C07K14/81 , C07K5/00 , A61K37/02
Abstract: A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R2)- wherein R2 is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH2- or (3) -N(R2)- wherein R2 is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH2- and with the proviso that U is -C(O)- or -CH2- when W is -N(R2)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-when U is -N(R2)-; Q is -CH(R1)- or -C(=CHR1a)- wherein R1 is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH2- or -CH(OH)- or A is hydrogen when R1 is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R3 is a functional group; R4 is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R5 is -CH(OH)- or -C(O)-; R6 is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
-
公开(公告)号:CA2017252A1
公开(公告)日:1990-11-23
申请号:CA2017252
申请日:1990-05-22
Applicant: ABBOTT LAB
Inventor: KEMPF DALE J , NORBECK DANIEL W , ERICKSON JOHN W , SHAM HING L , CODACOVI LYNN M , PLATTNER JACOB J
IPC: C07D295/18 , A61K31/00 , A61K31/10 , A61K31/12 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/195 , A61K31/335 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/47 , A61K31/495 , A61K31/535 , A61K31/54 , A61K38/00 , A61P31/12 , A61P37/04 , C07C31/125 , C07C33/18 , C07C33/26 , C07C33/46 , C07C39/12 , C07C43/164 , C07C43/174 , C07C43/205 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/313 , C07C43/315 , C07C45/00 , C07C45/29 , C07C45/56 , C07C45/59 , C07C45/62 , C07C45/67 , C07C45/74 , C07C49/04 , C07C49/12 , C07C49/17 , C07C49/175 , C07C49/20 , C07C49/215 , C07C49/233 , C07C49/24 , C07C49/255 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/06 , C07C215/18 , C07C215/20 , C07C215/28 , C07C217/04 , C07C225/06 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/35 , C07C233/36 , C07C233/40 , C07C233/78 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/04 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/08 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/00 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/05 , C07C311/06 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/11 , C07C323/12 , C07C323/25 , C07C323/41 , C07C323/60 , C07C381/00 , C07D207/06 , C07D207/08 , C07D207/12 , C07D207/16 , C07D207/24 , C07D209/42 , C07D211/22 , C07D211/54 , C07D211/62 , C07D211/96 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/55 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/14 , C07D217/16 , C07D217/26 , C07D231/10 , C07D233/60 , C07D233/61 , C07D233/84 , C07D239/38 , C07D263/06 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D279/12 , C07D295/088 , C07D295/14 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/20 , C07D295/205 , C07D295/215 , C07D295/22 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D305/14 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D521/00 , C07F7/02 , C07F9/30 , C07F9/32 , C07F9/53 , C07K5/02 , C07K5/04 , C07K5/06 , C07K5/062 , C07K5/078 , C07C33/00 , A61K38/05
Abstract: A retroviral protease inhibiting compound of the formula A-X-B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, -332- (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.
-
公开(公告)号:CY1110361T1
公开(公告)日:2015-04-29
申请号:CY071101364
申请日:2007-10-23
Applicant: ABBOTT LAB
Inventor: MADAR DAVID , PEI ZHONGHUA , PIREH DAISY , DJURIC STEVAN W , WIEDEMAN PAUL E , YONG HONG , MICHMERHUIZEN MELISSA J , KOPECKA HANA , LI XIAOFENG , LONGENECKER KENTON , SHAM HING L , STEWART KENT D , SZCZEPANKIEWICZ BRUCE G
IPC: C07D207/00 , A61P37/02 , C07D207/16 , C07D207/26 , C07D207/27 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: ΗπαρούσαεφεύρεσησχετίζεταιμεενώσειςτουτύπουΙ οιοποίεςαναστέλλουντηνδιπεπτιδυλικήπεπτιδάση IV (DPP-IV) καιείναιχρήσιμεςγιατηνπρόληψηή τηναγωγήτουδιαβήτη, ειδικάτουδιαβήτητύπουΙΙ, όπωςεπίσηςτηςυπεργλυκαιμίας, τουΣυνδρόμουΧ, τηςυπερινσουλιναιμίας, τηςπαχυσαρκίας, τηςαθηροσκλήρωσης, καιδιαφόρωνανοσορρυθμιστικώννόσων. Ήφαρμακευτικώςαποδεκτάάλαταή προφάρμακααυτών, όπουτα X, R, R1, R2 και R3 έχουντουςορισμούςπουδίνονταιστηνπεριγραφή.
-
74.
公开(公告)号:SK286686B6
公开(公告)日:2009-03-05
申请号:SK8232003
申请日:2001-11-30
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY STEPHEN L II , HASVOLD LISA A , LI QUN , LI TOMGMEI , LIN NAN-HORNG , MANTEI ROBERT A , ROCKWAY TODD W , SHAM HING L , SULLIVAN GERARD M , TONG YUNSONG , WANG GARY T , WANG LE , WANG XILU , WANG WEIBO
IPC: C07D233/00 , A61K31/00 , A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/00 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Disclosed are substituted imidazoles and thiazoles having formula (I) useful for inhibiting farnesyltransferase and also disclosed are farnesyltransferase-inhibiting compositions and the use these compounds in the production of medicaments for inhibiting farnesyltransferase.
-
公开(公告)号:DK0997459T3
公开(公告)日:2009-03-02
申请号:DK00101297
申请日:1991-11-04
Applicant: ABBOTT LAB
Inventor: KEMPF DALE J , ZHAO CHEN , CODACOVI LYNN M , PLATTNER JACOB J , WITTENBERGER STEVEN J , NORBECK DANIEL W , SHAM HING L
IPC: A61K31/42 , C07D277/24 , A61K31/421 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/435 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/444 , A61K38/00 , A61P31/12 , A61P31/18 , A61P43/00 , C07C53/134 , C07C211/00 , C07C215/18 , C07C215/20 , C07C215/28 , C07C215/30 , C07C215/80 , C07C219/18 , C07C233/40 , C07C237/10 , C07C237/22 , C07C269/04 , C07C271/02 , C07C271/16 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/24 , C07D20060101 , C07D213/00 , C07D213/26 , C07D213/30 , C07D213/34 , C07D213/36 , C07D213/40 , C07D213/54 , C07D213/56 , C07D213/61 , C07D213/75 , C07D213/79 , C07D215/20 , C07D233/54 , C07D233/84 , C07D235/14 , C07D235/16 , C07D237/10 , C07D239/26 , C07D241/12 , C07D261/08 , C07D261/12 , C07D263/20 , C07D263/32 , C07D277/20 , C07D277/28 , C07D277/30 , C07D277/32 , C07D277/34 , C07D277/36 , C07D277/40 , C07D277/42 , C07D277/56 , C07D295/02 , C07D295/13 , C07D295/205 , C07D295/215 , C07D303/36 , C07D307/34 , C07D307/42 , C07D307/66 , C07D333/16 , C07D333/36 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D521/00 , C07K1/113 , C07K5/06 , C07K5/065 , C07K5/08 , C07K14/81
Abstract: An intermediate of the formula: and an intermediate of the formula: or an acid addition salt thereof.M
-
公开(公告)号:HK1082733A1
公开(公告)日:2006-06-16
申请号:HK06101745
申请日:2006-02-09
Applicant: ABBOTT LAB
Inventor: MADAR DAVID , PEI ZHONGHUA , PIREH DAISY , DJURIC STEVAN W , PAUL WIEDEMAN E , HONG YONG , FEENSTRA MELISSA J , KOPECKA HANA , LI XIAOFENG , LONGENECKER KENTON , SHAM HING L , STEWART KENT D , SZCZEPANKIEWICZ BRUCE G
IPC: C07D20060101 , A61P37/02 , C07D207/16 , C07D207/26 , C07D207/27 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.
-
公开(公告)号:AR041289A1
公开(公告)日:2005-05-11
申请号:ARP030103370
申请日:2003-09-17
Applicant: ABBOTT LAB
Inventor: FEENSTRA MELISSA , KOPECKA HANA , LI LI , LONGENECKER K , SHAM HING L , STEWART KENT D , MADAR DAVID , PEI ZHONGHUA , PIREH DAISY , DJURIC STEVAN W , WIEDEMAN PAUL E , YONG HONG , SZCZEPANKIEWICZ BRUCE G
IPC: C07D207/16 , A61K31/4025 , A61K31/428 , A61K31/4439 , A61K31/4523 , A61K31/4709 , A61P3/04 , A61P3/10 , A61P5/50 , A61P37/02 , C07D207/26 , C07D207/277 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12 , C07F5/00
Abstract: Compuestos que inhiben la dipeptidil peptidasa IV (DPP-IV) y son de utilidad en la prevención o tratamiento de la diabetes, especialmente la diabetes de tipo II, y también de la hiperglucemia, el Síndrome X, la hiperinsulinemia, la obesidad, laarterosclerosis, y diversas enfermedades inmunomoduladoras. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), o una sal o prodroga aceptable para uso farmacéutico del mismo, donde X es un miembro seleccionado entre elgrupo que comprende CH2, CHF y CF2; R se selecciona entre el grupo que comprende alquilcarbonilo, arilcarbonilo, ciano, heterociclilcarbonilo, R4R5NC(O)-, B(OR6)2, (1,2,3)-dioxoborolano y 4,4,5,5-tetrametil-(1,2,3)-dioxoborolano; R1 se seleccionaentre el grupo que comprende alcoxialquilo, alquilo, alquilcarbonilo, alquenilo, alquinilo, alenilo, arilaquilo, cicloalquilo, cicloalquilalquilo, ciano, haloalquilo, haloalquenilo, heterociclilalquilo, e hidroxialquilo; R2 y R3 se seleccionan enforma independiente entre el grupo que comprende hidrógeno, alcoxialquilo, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heterociclo, heterociclilalquilo, hidroxialquilo; o R2 y R3 junto con los átomos a loscuales están unidos forman un heterociclo mono o bicíclico seleccionado entre el grupo que comprende 2-indolinilo, 2-indolilo, 3-isoquinolina, 2-piperazina, 2-piperidina, 2-pirrolidina, 2-pirrol, 2-piridina, 2-quinolinilo, 2-tetrahidroquinolinilo, y3-tetrahidroisoquinolinilo, donde dicho heterociclo puede estar sustituido con 0, 1, 2 o 3 sustituyentes seleccionados en forma independiente entre alquenilo, alcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilo,alquilcarbonilalquilo, alquilcarboniloxi, alquilsulfonilo, alquiltio, alquinilo, arilo, arilalcoxi, arilalquilo, arilcarbonilo, ariloxi, carboxi, carboxialquilo, ciano, cianoalquilo, formilo, halógeno, haloalquilo, hidroxi, hidroxialquilo, mercapto,nitro, fenilo, RaRbN-, RcRdNC(O)-, y RcRdNS(O)2-; R4, R5 y R6 se seleccionan cada uno en forma independiente entre el grupo que comprende hidrógeno, alquilo, y arilalquilo; Ra y Rb se selecciona cada uno en forma independiente entre el grupo quecomprende alquilo, alquilcarbonilo, alcoxicarbonilo, alquilsulfonilo; o Ra y Rb junto con el nitrógeno al cual están unidos forman un anillo seleccionado entre el grupo que comprende piperidina, piperazina y morfolina; y Rc y Rd se seleccionan cadauno en forma independiente entre el grupo que comprende hidrógeno y alquilo.
-
公开(公告)号:HK1059260A1
公开(公告)日:2004-06-25
申请号:HK04100551
申请日:2004-01-27
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY STEPHEN L II , HASVOLD LISA A , LI QUN , LI TOMGMEI , LIN NAN-HORNG , MANTEI ROBERT A , ROCKWAY TODD W , SHAM HING L , SULLIVAN GERARD M , TONG YUNSONG , WANG GARY T , WANG LE , WANG XILU , WANG WEIBO
IPC: C07D20060101 , A61K20060101 , A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P20060101 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
-
公开(公告)号:AR035375A1
公开(公告)日:2004-05-12
申请号:ARP010105568
申请日:2001-11-29
Applicant: ABBOTT LAB
Inventor: SHAM HING L , WANG GARY , WANG LE , WANG WEI-BO , WANG XILU , HASVOLD LISA A , CLAIBORNE AKIYO K , LI QUN , LI TONGMEI , MANTEI ROBERT A , ROCKWAY TODD W , SULLIVAN GERARD M , TONG YUNSONG , LIN NAN-HORNG , GWALTNEY STEPHEN L
IPC: A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/14 , A61K31/695 , A61K31/55 , A61K31/454
Abstract: Un compuesto derivado de pirrol sustituido de fórmula (1) o una sal aceptable para uso terapéutico del mismo, donde E es un anillo carbocíclico aromático o no aromático de cinco, seis o siete miembros donde entre cero y tres átomos de carbono están reemplazados por nitrógeno; F y G son independientemente seleccionados del grupo formado por C y N; con la salvedad de que cuando uno de F y G es N, el otro es C; L1 y L2 son cada uno independientemente seleccionados del grupo formado por un enlace C2 alquileno, C2 alquinileno, O, NR9, C(O), S, S(O). SO2, SO2NR9, NR9SO2, C(O)NR9, NR9C(O), y CO2; X se selecciona entre el grupo formado por S y NR7; R1 se selecciona entre en grupo formado por arilo, arilalquilo, heterociclo, y (heterociclo)alquilo; R2 se selecciona entre el grupo formado por hidrógeno, alcoxi, alquilo, amino, aminoalquilo, ciano, cianoalquilo, cicloalquilo, cicloalquilalquilo, halo, haloalquilo, heterociclo, (heterociclo)alquilo, hidroxilo, e hidroxialquilo; R3 se selecciona entre el grupo formado por arilo, heterociclo y cicloalquil; R4-6 son cada uno independientemente seleccionado del grupo formado por hidrógeno NR9C(O), C(O)NR9, alcanoilo, alquenilo, alcoxi, alcoxialquilo, alquilo, alquilsulfonilo, alquinilo, amido, amino, aminoalquilo, aminosulfonilo, arilo, arilalquilo, ariloxi, arilsulfonilo; azido, carboxi, ciano, cianoalquilo, cicloalquilo, cicloalquilalquilo, halo, haloalcoxi, haloalquilo, heterociclo, (heterociclo)alquilo, hidroxilo, hidroxialquilo, nitro, nitroalquilo, oxo, y tio(oxo); R7 se selecciona entre el grupo formado por hidrógeno, alquilo, arilo, cicloalquilo, cicloalquilalquilo, heterociclo (heterociclo)alquilo, y trialquilsililo; R9 se selecciona entre el grupo formado por hidrógeno, alcoxialquilo, alquil, amidoalquilo, aminoalquilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, carboxialquilo, heterociclo (heterociclo), alquilo, hidroxialquilo, y un grupo protector de nitrógeno; cada R12 se selecciona independientemente del grupo formado por hidrógeno, alcoxi, alquilo, amino, halo e hidroxilo; m es 0, 1, 2, 3, o 4; n es 0, 1, 2, 3 o 4; p es 0, 1, 2, 3 o 4; y q es 0, 1, 2, 3, o 4. También se revelan composiciones inhibidoras de la farnesiltransferasa y el uso de dichos compuestos en la fabricación de medicamentos para inhibir la farnesiltransferasa en un paciente.
-
公开(公告)号:CA2497725A1
公开(公告)日:2004-04-01
申请号:CA2497725
申请日:2003-09-15
Applicant: ABBOTT LAB
Inventor: MADAR DAVID , KOPECKA HANA , LI XIAOFENG , FEENSTRA MELISSA J , SZCZEPANKIEWICZ BRUCE G , STEWART KENT D , PEI ZHONGHUA , YONG HONG , WIEDEMAN PAUL E , DJURIC STEVAN W , PIREH DAISY , LONGENECKER KENTON , SHAM HING L
IPC: A61P37/02 , C07D207/16 , C07D207/26 , C07D207/27 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D417/12 , A61K31/401 , A61K31/4439 , A61K31/506
Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia , Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R1,R2 and R3 have the definitions given in the description.
-
-
-
-
-
-
-
-
-